Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), GlaxoSmithKline (GSK – Research Report) and AbbVie (ABBV – Research Report).
Amgen (AMGN)
BMO Capital analyst Evan Seigerman assigned a Hold rating to Amgen yesterday and set a price target of $253.00. The company’s shares closed last Tuesday at $252.40.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Hold with an average price target of $264.93, representing a 4.4% upside. In a report issued on January 30, UBS also maintained a Hold rating on the stock with a $260.00 price target.
See the top stocks recommended by analysts >>
GlaxoSmithKline (GSK)
In a report released today, Graham Parry from Bank of America Securities maintained a Sell rating on GlaxoSmithKline, with a price target of p1495.00. The company’s shares closed last Tuesday at $35.26.
Parry has an average return of
According to TipRanks.com, Parry is ranked #3524 out of 8305 analysts.
Currently, the analyst consensus on GlaxoSmithKline is a Moderate Sell with an average price target of $20.27.
AbbVie (ABBV)
BMO Capital analyst Gary Nachman maintained a Buy rating on AbbVie yesterday and set a price target of $169.00. The company’s shares closed last Tuesday at $147.75.
According to TipRanks.com, Nachman has 0 stars on 0-5 stars ranking scale with an average return of
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $163.15, which is a 12.0% upside from current levels. In a report issued on January 17, Piper Sandler also maintained a Buy rating on the stock with a $157.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMGN:
- AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
- AbbVie’s Humira drug faces competition in the U.S., FT reports
- Amgen announces Humira biosimilar now available in the U.S.
- Amgen lays off 300 employees, or 1.2% of workforce, Reuters reports
- Can Amgen (AMGN) Q4 Earnings Beat Street Expectations?
